Skin Cancer

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
Research Papers
Connections
Featured Videos

1. Overview

Skin cancer is by far the most common cancer in the United States — more people are diagnosed with skin cancer each year than all other cancers combined. An estimated 5 million Americans are treated for skin cancer every year, and roughly one in five Americans will develop it by age 70. The good news, and it is genuinely good news, is that the overwhelming majority of skin cancers are highly curable when found early. The skin is the one organ you can examine yourself, every day, without a single test — which makes skin cancer one of the few cancers where your own eyes can save your life.

There are three main types, and understanding the difference between them matters more than almost anything else on this page:

Basal cell carcinoma (BCC) — the most common cancer of any kind in humans, accounting for about 80% of skin cancers. It grows out of the basal cells at the bottom of the epidermis (the skin's outer layer). BCC grows slowly and almost never spreads to other organs — it is locally destructive rather than life-threatening. Left alone for years it can erode into surrounding tissue (older textbooks called it a "rodent ulcer"), but caught early it is removed in a single office visit.
Squamous cell carcinoma (SCC) — the second most common type, arising from the flat squamous cells higher in the epidermis. SCC is usually curable, but unlike BCC it can spread (metastasize) in roughly 2–5% of cases, especially when it grows on the lip or ear, gets large, or develops in someone with a weakened immune system. Many SCCs announce themselves years in advance as actinic keratoses — rough, sandpapery pink patches on sun-exposed skin that are precancerous and easy to treat.
Melanoma — the least common of the three but by far the most dangerous, because it metastasizes early relative to its size. Melanoma arises from melanocytes, the pigment-producing cells, and causes about 8,000 deaths per year in the US — the large majority of all skin-cancer deaths despite being only about 1% of skin-cancer cases. A melanoma the thickness of two dimes can already be life-threatening; one caught at the width of a pencil eraser but still thin is almost always cured.

The central theme of this article is a hopeful one: skin cancer is largely preventable (most cases trace back to ultraviolet light), largely detectable by you (the ABCDE rule and "ugly duckling" sign below take five minutes to learn), and — even at the advanced stage that was a death sentence fifteen years ago — increasingly treatable, thanks to immunotherapy drugs that have transformed metastatic melanoma from a disease with months of expected survival into one where roughly half of patients in major trials are alive at five years.

2. Epidemiology

Because most basal and squamous cell carcinomas are treated in dermatology offices and never reported to cancer registries, exact counts are estimates. The most-cited analysis, published in JAMA Dermatology in 2015, estimated 5.4 million keratinocyte carcinomas (BCC + SCC) treated in 3.3 million Americans in a single year — and incidence has continued to rise since. For melanoma, which registries do track, the American Cancer Society estimates roughly 100,000 new invasive melanomas and about 8,000 deaths per year in the US.

Key patterns worth knowing:

Incidence rises steeply with age — most skin cancers appear after 50, reflecting decades of accumulated sun damage. But melanoma is unusual among cancers in striking the young: it is one of the most common cancers in adults under 30, particularly young women, a pattern linked to indoor tanning.
Men over 50 carry the highest melanoma death risk. Men are more likely to develop melanoma on the back and scalp (hard to self-inspect), present later, and die more often than women at every age.
Fair-skinned populations bear most of the burden. Lifetime melanoma risk is roughly 1 in 33 for white Americans versus about 1 in 1,000 for Black Americans.
But darker skin is not immune — and outcomes are worse when cancer does occur. In people with darker skin, melanoma disproportionately appears on the palms, soles, and under the nails (acral lentiginous melanoma) — sites with little to do with sun exposure and that nobody thinks to check. Because these melanomas are found later, five-year survival for Black melanoma patients lags significantly behind that of white patients. Reggae legend Bob Marley died at 36 of an acral melanoma that began under a toenail — initially dismissed as a soccer bruise. His story is the standard teaching example for a reason: a dark streak in a nail, or a new dark spot on a palm or sole, deserves a dermatologist's eyes regardless of your skin tone.
Geography matters. Australia and New Zealand — fair-skinned populations under intense UV — have the world's highest rates, which is why much of the best prevention research (the Nambour and ONTRAC trials discussed below) is Australian.

3. Pathophysiology

Skin cancer is, at its core, a disease of DNA damage from ultraviolet (UV) light accumulating faster than the skin can repair it. The mechanism is unusually well understood — UV damage leaves a literal molecular fingerprint in the tumor's DNA.

How UV light damages DNA

UVB (290–320 nm) is the burning wavelength. It is absorbed directly by DNA, fusing adjacent pyrimidine bases into cyclobutane pyrimidine dimers — kinks in the DNA strand. When the cell copies damaged DNA, it makes characteristic C→T spelling errors. These "UV signature mutations" are so distinctive that scientists can read a skin tumor's genome and see the sunburns written into it. Skin cancers carry among the highest mutation counts of any human cancer.
UVA (320–400 nm) penetrates deeper into the dermis, generates reactive oxygen species that oxidize DNA indirectly, drives photoaging (wrinkles, leathery texture), and contributes to melanoma. UVA passes through window glass and was historically the dominant output of tanning beds, which the WHO's International Agency for Research on Cancer (IARC) classifies as a Group 1 carcinogen — the same top-certainty category as tobacco and asbestos. A meta-analysis in the BMJ found that ever using a sunbed raises melanoma risk by about 20%, and first use before age 35 raises it by nearly 60%.

The gatekeeper genes

Basal cell carcinoma is driven almost universally by uncontrolled Hedgehog pathway signaling — most often a damaged PTCH1 gene, the pathway's brake. This discovery led directly to the targeted drugs vismodegib and sonidegib for the rare advanced cases.
Squamous cell carcinoma typically begins with UV-mutated p53, the genome's "guardian" gene. With p53 disabled, sun-damaged cells that should self-destruct survive and accumulate further mutations — the visible intermediate stage being the actinic keratosis.
Melanoma carries an activating BRAF V600E mutation in roughly half of cases, jamming the MAPK growth-signaling pathway in the "on" position. NRAS mutations account for another ~20%, and KIT mutations are enriched in acral and mucosal melanomas. The BRAF discovery is the foundation of modern targeted therapy (Section 7).

Why the immune system is central

Healthy immune surveillance constantly removes UV-mutated cells — this is why organ-transplant recipients on immunosuppressant drugs develop SCC at up to 65–100 times the normal rate. It is also why melanoma, packed with mutant proteins the immune system can recognize, responds so dramatically to checkpoint inhibitor immunotherapy: the cancer survives by switching off attacking T-cells, and these drugs flip the switch back on.

4. Etiology and Risk Factors

UV exposure is the dominant cause, but risk is the product of exposure and susceptibility. The highest-risk profile is well defined:

Fair skin that burns easily (Fitzpatrick types I–II): red or blond hair, blue or green eyes, freckling. Melanin is natural sunscreen; less of it means more UV reaches DNA.
Blistering sunburns in childhood and adolescence. Intense, intermittent burns — especially early in life — are more strongly linked to melanoma and BCC than the same total UV spread evenly. A handful of bad childhood sunburns measurably raises lifetime melanoma risk, which is why protecting children is the single highest-leverage prevention act.
Many moles, or atypical moles. Having more than 50 common moles, or any "dysplastic" (atypical) nevi, marks melanocytes prone to misbehavior. Most melanomas, however, arise on previously normal skin — not from existing moles.
Family and personal history. A first-degree relative with melanoma roughly doubles your risk; rare families carry CDKN2A mutations with very high risk. And one skin cancer of any type strongly predicts more — a first BCC or SCC is the best-validated signal to start annual skin checks.
Immunosuppression. Organ-transplant medications, chronic lymphocytic leukemia, and long-term high-dose corticosteroids dramatically raise risk, SCC most of all. Transplant recipients need dermatologic surveillance as a standing part of their care.
Tanning beds — IARC Group 1 carcinogen, with risk concentrated in users under 35 (see Section 3). There is no safe cosmetic tan from a UV device.
Chronic skin injury and other carcinogens. SCC can arise in old burn scars and chronic wounds (Marjolin ulcer), from arsenic exposure (historically contaminated well water), from ionizing radiation, and — on the lips — with tobacco use.
Cumulative occupational sun. Decades of outdoor work (farming, construction, fishing) drives SCC in particular, which maps neatly onto the most sun-hammered real estate: ears, lower lip, scalp, forearms, backs of hands.

And the exception that matters: acral melanoma — palms, soles, nail beds — occurs at roughly the same absolute rate across all skin tones and is not primarily a sun cancer. Its risk factors are less understood. The practical takeaway for readers with darker skin is not to worry about sunburn statistics but to include palms, soles, and nails in every self-exam, because these are precisely the melanomas found late.

5. Clinical Presentation

What each type looks like

Basal cell carcinoma: classically a pearly or waxy bump with a rolled, translucent border and fine surface blood vessels (telangiectasias), often on the face, ears, or neck. It may look like a pimple or sore that bleeds easily, scabs, seems to heal, and comes back — that cycle repeating over months is BCC until proven otherwise. Flatter, scar-like, or pink-patch variants exist.
Squamous cell carcinoma: a firm, red, scaly or crusted nodule or a flat sore that won't heal, on sun-exposed skin — ears, lower lip, scalp, forearms, hands. Often tender, sometimes growing quickly over weeks. Its precursor, the actinic keratosis, is a small rough patch you often feel (like fine sandpaper) before you see it. Only a small percentage of actinic keratoses progress to SCC, but treating them is easy and removes the risk.
Melanoma: usually a new or changing dark spot. In men most often the back; in women the legs; in darker skin the palms, soles, and nails. Some melanomas are red or skin-colored (amelanotic) — change and asymmetry matter more than darkness.

The ABCDE rule for melanoma

A — Asymmetry: one half doesn't match the other.
B — Border: edges are ragged, notched, or blurred rather than smooth.
C — Color: multiple shades in one spot — browns, blacks, or patches of red, white, or blue.
D — Diameter: larger than about 6 mm (a pencil eraser) — though melanomas can be smaller.
E — Evolving: changing in size, shape, color, or elevation, or newly itching or bleeding. E is the most important letter. A stable spot for twenty years is rarely the problem; the one that's different from last month is.

The "ugly duckling" sign

Most people's moles resemble each other — they share a family look. A melanoma usually doesn't match the family. Scan your skin and ask: does one spot stand out as darker, larger, or simply different from all its neighbors? That outlier — the ugly duckling — deserves attention even if it fails every ABCDE letter. This single heuristic catches melanomas that checklists miss.

How to do a monthly self-exam (5 minutes)

After a shower, in good light, with a full-length mirror and a hand mirror.
Front, back, left and right sides with arms raised. Use the hand mirror (or a partner, or a phone photo) for your back, scalp, and the backs of your legs.
Forearms, underarms, and palms. Check between fingers and under fingernails and toenails — a new brown-black streak running the length of a nail, especially one widening or spilling pigment onto the surrounding skin, needs evaluation.
Soles of the feet and between the toes.
Photograph anything you're watching, next to a coin for scale. A photo from last month settles "is it changing?" better than memory ever will.

If you find something: don't panic, and don't wait. Most worrisome-looking spots turn out benign — but the visit is quick, and a biopsy is a minor office procedure. The cost of checking is trivial; the cost of waiting can be anything but.

6. Diagnosis

From spot to answer

Clinical exam and dermoscopy. A dermatologist examines the lesion with a dermatoscope — a lit magnifier that reveals pigment networks and vessel patterns invisible to the naked eye. Dermoscopy substantially improves melanoma detection accuracy over the naked eye and spares many benign moles from biopsy.
Biopsy. The only way to diagnose skin cancer is under the microscope. For suspected BCC/SCC, a quick shave or punch biopsy under local anesthetic suffices. For a suspected melanoma, guidelines prefer an excisional biopsy — removing the whole lesion with a narrow margin — because the pathologist must measure the tumor's full depth, and a partial sample can literally cut that measurement short.
Pathology report. For melanoma, this report contains the single most important number in this entire disease.

Breslow depth — the number that drives everything

In 1970, surgeon Alexander Breslow showed that a melanoma's vertical thickness in millimeters — measured from the top of the skin's granular layer to the deepest cancer cell — predicts survival better than any other feature. Fifty-five years later, Breslow depth is still the backbone of melanoma staging:

≤0.8 mm, no ulceration: very low risk; wide excision is usually the whole treatment, and cure rates approach 99%.
0.8–1.0 mm, or any thin melanoma with ulceration: still excellent outlook; sentinel node biopsy is discussed.
1–4 mm: intermediate thickness; sentinel lymph node biopsy is routinely offered to stage the nearest lymph nodes.
>4 mm: high-risk; staging work-up and adjuvant (post-surgery) drug therapy enter the conversation.

If you or a family member is diagnosed with melanoma, ask two questions first: "What is the Breslow depth?" and "Is it ulcerated?" Those two answers frame everything that follows.

Staging beyond the skin

Sentinel lymph node biopsy (SLNB) — injecting a tracer at the tumor site to find and remove the first ("sentinel") lymph node draining it — tells you whether melanoma has taken its first step outward. The landmark MSLT-I trial established SLNB as the standard staging tool for intermediate-thickness melanoma. For confirmed node-positive or thicker tumors, PET/CT or CT imaging and a blood LDH level complete staging under the AJCC (8th edition) system, which runs from stage 0 (in situ — confined to the epidermis, essentially 100% curable) to stage IV (distant spread). Molecular testing of advanced tumors for BRAF mutation is now routine because it determines drug options. BCC and SCC rarely need any of this — biopsy plus exam is usually the complete work-up.

7. Treatment

Basal cell and squamous cell carcinoma

Standard surgical excision — removal with a few millimeters of healthy margin under local anesthetic — cures the large majority of BCCs and SCCs in a single visit.
Mohs micrographic surgery, developed by Dr. Frederic Mohs beginning in the 1930s, deserves a plain-language explanation because it sounds more intimidating than it is. The surgeon removes the visible tumor plus a thin rim of tissue, then — while you wait — freezes, slices, and examines 100% of the margin under a microscope, mapping exactly where (if anywhere) tumor cells remain. Only those map locations are re-excised, and the cycle repeats until the margins are clean. The result: the highest cure rates of any technique (~99% for primary BCC) while removing the least possible healthy tissue. It is the preferred option for cancers on the face, nose, ears, and eyelids, for large or recurrent tumors, and for aggressive subtypes. Expect to spend a half-day at the office; most of it is waiting on the microscope.
Destruction techniques — curettage and electrodesiccation (scrape and cauterize) or cryotherapy — work well for small, low-risk tumors on the trunk and limbs.
Topical therapy for superficial disease: 5-fluorouracil (5-FU) cream, a chemotherapy that selectively kills sun-damaged cells, and imiquimod, which summons a local immune attack, treat superficial BCCs and fields of actinic keratoses. Fair warning your dermatologist will repeat: treated skin gets red, raw, and crusted for two to four weeks — that inflammation is the treatment working. Photodynamic therapy (a light-activated sensitizing cream) is another field treatment for actinic keratoses.
Radiation therapy is an option for patients who can't undergo surgery or for tumors in surgically difficult locations.
Advanced disease: for the rare BCC too extensive for surgery, Hedgehog-pathway inhibitors (vismodegib, sonidegib) shrink tumors by blocking the pathway broken in Section 3. For advanced or metastatic SCC, the checkpoint-inhibitor antibody cemiplimab produces durable responses in a substantial fraction of patients.

Melanoma

Wide local excision. The diagnosed melanoma site is re-excised with a safety margin scaled to Breslow depth (roughly 1 cm for thin tumors, 2 cm for thick ones). For thin melanomas this is the entire treatment.
Sentinel lymph node biopsy for intermediate/thick tumors, as above. A positive sentinel node no longer automatically means removing all the nodes — trials showed careful ultrasound surveillance gives equal survival with far less lymphedema — but it does open the door to adjuvant drug therapy.
Checkpoint inhibitor immunotherapy — the revolution. Until 2011, metastatic melanoma had a median survival of well under a year and no drug proven to extend life. That year, ipilimumab (anti-CTLA-4) became the first, and the PD-1 antibodies nivolumab and pembrolizumab that followed were better still. These drugs don't poison the cancer; they release the brakes melanoma places on the patient's own T-cells. In the CheckMate 067 trial, the nivolumab-plus-ipilimumab combination produced five-year overall survival of about 52% in stage IV melanoma — patients who would previously have been given months. Many long responders remain disease-free years after stopping treatment, a word oncologists once never used in stage IV melanoma: durable. These drugs now also serve as adjuvant therapy (after surgery for high-risk stage III disease) to cut recurrence risk.
BRAF/MEK targeted therapy. For the ~half of melanomas carrying a BRAF V600 mutation, oral inhibitor pairs — dabrafenib + trametinib, vemurafenib + cobimetinib, encorafenib + binimetinib — switch off the jammed growth signal. Responses are fast and frequent (useful when disease is bulky or symptomatic), though resistance often develops over time, so these are typically sequenced with immunotherapy.
What this means practically: if you are diagnosed with stage III or IV melanoma, ask for BRAF testing, ask whether adjuvant immunotherapy applies to you, and strongly consider a consultation at an academic melanoma center — trial access and sequencing expertise measurably matter in this fast-moving field. Checkpoint inhibitors are expensive but FDA-approved and covered by Medicare and most insurers for approved indications; the manufacturers and many centers run patient-assistance programs worth asking about on day one.

8. Complications

Local destruction and disfigurement. Neglected BCCs can invade cartilage and bone, particularly on the nose and ear; large excisions on the face may need reconstructive flaps or grafts. Early treatment is the best cosmetic strategy as well as the best cancer strategy.
Metastasis. SCC spreads first to regional lymph nodes (highest risk: lip, ear, large or deep tumors, immunosuppressed patients). Melanoma can spread to nodes, lungs, liver, bone, and — distinctively often — the brain, which is why neurologic symptoms in a melanoma survivor always warrant imaging. Modern immunotherapy and stereotactic radiosurgery have substantially improved outcomes even for brain metastases.
Recurrence and field cancerization. One skin cancer marks the whole sun-exposed "field" as at-risk: roughly 40–50% of patients with a first BCC develop another skin cancer within five years. Lifelong annual (or more frequent) skin checks become part of your routine.
Lymphedema — chronic limb swelling — can follow lymph node dissection; the move away from routine complete dissections has made it much less common.
Immune-related side effects of checkpoint inhibitors. Releasing T-cell brakes can let the immune system attack healthy organs: thyroid (very common, usually manageable with hormone replacement), colon (colitis with diarrhea), skin, liver, pituitary, and rarely lungs or heart. Most are reversible when caught early and treated with corticosteroids — which is why patients on immunotherapy are told to report any new symptom promptly rather than tough it out.
The emotional weight. A melanoma diagnosis in particular brings real scan-to-scan anxiety. It is normal, it is common, and melanoma support communities (AIM at Melanoma, the Melanoma Research Foundation forums) are unusually strong — survivors of the immunotherapy era have much to be hopeful about and are vocal about it.

9. Prognosis

Honest numbers, type by type:

Basal cell carcinoma: essentially never fatal when treated; cure rates with surgery exceed 95–99%. The realistic "risk" is more skin cancers later, not this one spreading.
Squamous cell carcinoma: overall cure rates above 90–95%. The minority that metastasize (~2–5%, higher for lip/ear tumors and immunosuppressed patients) are serious, which is why high-risk SCCs get closer follow-up and sometimes radiation or immunotherapy.
Melanoma — by stage at diagnosis (US SEER five-year relative survival):
- Localized (confined to the skin): ~99%. Most melanomas are caught here. This number is the entire argument for self-exams.
- Regional (spread to nearby nodes): ~70–75%, and improving as adjuvant immunotherapy reshapes stage III outcomes.
- Distant (stage IV): ~35% in registry data — a number that would have read under 10% in 2010. Registry figures lag the clinic: in the CheckMate 067 trial, combination immunotherapy delivered ~50% five-year survival in metastatic melanoma, and updated follow-up shows many of those survivors remain well past ten years. Stage IV melanoma is now a disease some patients are effectively cured of — a sentence no honest article could have printed fifteen years ago.

Within melanoma, the strongest individual predictors remain Breslow depth, ulceration, and sentinel node status — plus age, site, and mitotic activity. Two melanomas of identical stage can behave differently, so treat survival statistics as the map, not the territory: they describe groups, not you.

10. Prevention

Sunscreen — what the evidence actually shows

Sunscreen skepticism is common, so it's worth being precise about the proof. The Nambour trial in Queensland, Australia randomized over 1,600 adults to daily SPF 16 sunscreen on the head and arms versus their usual discretionary use, for nearly five years. Results: ~40% fewer squamous cell carcinomas during the trial, and — in the prespecified 10-year follow-up published in the Journal of Clinical Oncology — half as many melanomas (and ~73% fewer invasive melanomas) in the daily-sunscreen group. This remains the only randomized trial of sunscreen and melanoma, and it was positive. Sunscreen is not a marketing story; it is one of the few cancer-prevention interventions ever proven in a randomized trial.

Practical use: broad-spectrum (UVA + UVB), SPF 30 or higher, applied generously (most people apply a quarter to half the tested dose — about a shot-glass full covers an adult in swimwear) and reapplied every two hours outdoors or after swimming/sweating. Mineral (zinc oxide / titanium dioxide) formulas suit sensitive skin and work immediately on application.

Sun-smart habits beyond sunscreen

Shade between 10 a.m. and 4 p.m., when UV is strongest. The Australian slogan covers it: Slip on a shirt, slop on sunscreen, slap on a wide-brimmed hat, seek shade, slide on sunglasses.
Clothing outperforms sunscreen where it covers: a long-sleeved UPF 50 shirt never needs reapplying. Densely woven fabric works nearly as well.
Never use tanning beds (Group 1 carcinogen — Section 3). A "base tan" offers roughly SPF 3 of protection at the cost of guaranteed DNA damage.
Protect children especially. Childhood sunburns cast the longest shadow (Section 4). Hats, swim shirts, and shade for kids are a genuine investment in their 60-year-old selves.
Avoid burning, full stop. Intermittent intense burns — the office worker's beach-week pattern — are the melanoma pattern.

The vitamin D question — handled honestly

Readers of this site know vitamin D matters, and the tension is real: the same UVB that burns skin also makes vitamin D in it. Three honest points resolve most of the conflict. First, in real-world use sunscreen has not been shown to cause vitamin D deficiency — application is imperfect, and incidental UVB gets through; trial participants using daily sunscreen (including in Nambour-associated studies) maintained vitamin D levels comparable to controls. Second, vitamin D synthesis plateaus quickly — brief incidental exposure (10–15 minutes on arms and legs a few times weekly for fair skin) generates substantial vitamin D, while the extended baking that follows adds mostly DNA damage, because the skin destroys excess pre-vitamin D as fast as it makes it. Third, for anyone at meaningful skin-cancer risk — and certainly anyone with a skin-cancer history — a vitamin D3 supplement is the rational way to get D: it delivers a measurable, titratable dose with zero mutations. Test your 25(OH)D level, supplement to sufficiency, and let your skin off the hook. There is no skin-cancer-safe tan, but there is absolutely a vitamin-D-sufficient life without one.

Nicotinamide for high-risk patients — a cheap, evidence-backed option

The Australian ONTRAC trial (New England Journal of Medicine, 2015) randomized 386 patients who had already had at least two keratinocyte cancers to nicotinamide 500 mg twice daily (a form of vitamin B3) or placebo for 12 months. Nicotinamide cut new BCCs and SCCs by 23% and reduced actinic keratoses, apparently by boosting DNA repair and preventing UV-induced immune suppression in skin. Important specifics: the benefit appeared only in this high-risk, prior-skin-cancer population and faded after stopping the pills; it is nicotinamide (niacinamide), not niacin — no flushing, inexpensive, over-the-counter; and it is no substitute for sun protection. If you've had multiple skin cancers, it's a conversation worth having with your dermatologist. Dietary antioxidants with photoprotective evidence — lycopene and astaxanthin among them — are reasonable adjuncts, never replacements, for the measures above.

Screening

Monthly self-exams (Section 5) plus a baseline full-body dermatologist exam — then annually for anyone with risk factors, prior skin cancer, many moles, or a melanoma family history. High-risk patients may get total-body photography or serial dermoscopy ("mole mapping") so change, the most important sign, becomes objectively measurable.

11. Recent Research and Advances

Neoadjuvant immunotherapy — giving checkpoint inhibitors before melanoma surgery rather than only after — has produced striking results in stage III disease, with trials showing that a short pre-surgical course of PD-1-based therapy improves event-free survival versus surgery-then-adjuvant therapy. The tumor itself serves as the immune system's training ground before it is removed.
Tumor-infiltrating lymphocyte (TIL) therapy. In 2024 the FDA approved lifileucel, the first cell therapy for a solid tumor: T-cells are harvested from the patient's own melanoma, expanded by the billions in the lab, and reinfused. It offers a new option for patients whose melanoma resists checkpoint inhibitors.
Personalized mRNA cancer vaccines. An mRNA vaccine custom-built against each patient's tumor mutations, combined with pembrolizumab, reduced melanoma recurrence versus pembrolizumab alone in the randomized KEYNOTE-942 trial; phase 3 testing is under way. After decades of failed melanoma vaccines, this approach finally has randomized evidence behind it.
Relatlimab and new checkpoints. The LAG-3 inhibitor relatlimab, combined with nivolumab, is an approved frontline option — the first new checkpoint class since PD-1 — with combination efficacy at lower toxicity than ipilimumab-based pairing.
AI-assisted diagnosis. Deep-learning systems now classify dermoscopic images of skin lesions at dermatologist-level accuracy in controlled studies, and smartphone-based triage tools are in active (and appropriately cautious) clinical evaluation — promising for the majority of the world without easy dermatology access.
Liquid biopsy. Circulating tumor DNA (ctDNA) blood tests can detect molecular relapse of melanoma months before scans show it, and are moving into trials as tools to guide who needs adjuvant therapy and who can be spared it.
Refining who needs treatment at all. Trials continue to define which sentinel-node-positive patients can safely skip node dissection, which thin melanomas can skip sentinel biopsy, and which elderly patients with low-risk BCC are better served by observation than surgery — the quiet but important science of doing less.

12. References & Research

Historical Background

Skin cancer holds a singular place in medical history: it was the first cancer ever traced to an environmental cause. In 1775, London surgeon Percivall Pott observed that chimney sweeps — boys sent up flues from childhood — developed scrotal squamous cell carcinoma ("soot wart") at extraordinary rates, and correctly blamed the soot itself, founding occupational medicine and the entire concept of chemical carcinogenesis a century and a half before the responsible polycyclic aromatic hydrocarbons were isolated. In the 1930s and 1940s, Wisconsin surgeon Frederic Mohs developed his microscopically controlled excision technique, which evolved into the fresh-tissue Mohs micrographic surgery that today offers the highest cure rates in skin oncology. In 1970, Alexander Breslow showed that simple tumor thickness predicts melanoma survival, giving the field its enduring prognostic backbone. The modern turning point came in 2011, when ipilimumab became the first drug ever to extend survival in metastatic melanoma and vemurafenib proved that targeting the BRAF mutation worked — twin breakthroughs, published a year apart in the New England Journal of Medicine, that converted melanoma from oncology's grimmest diagnosis into the proving ground for the immunotherapy revolution now reshaping treatment of many cancers.

Key Research Papers

Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012. JAMA Dermatology. 2015;151(10):1081-1086.
Breslow A. Thickness, Cross-Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma. Annals of Surgery. 1970;172(5):902-908.
Abbasi NR, Shaw HM, Rigel DS, et al. Early Diagnosis of Cutaneous Melanoma: Revisiting the ABCD Criteria. JAMA. 2004;292(22):2771-2776.
Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ. 2012;345:e4757.
Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. The Lancet. 1999;354(9180):723-729.
Green AC, Williams GM, Logan V, Strutton GM. Reduced Melanoma After Regular Sunscreen Use: Randomized Trial Follow-Up. Journal of Clinical Oncology. 2011;29(3):257-263.
Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. New England Journal of Medicine. 2015;373(17):1618-1626.
Morton DL, Thompson JF, Cochran AJ, et al. Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. New England Journal of Medicine. 2014;370(7):599-609.
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians. 2017;67(6):472-492.
Hodi FS, O'Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine. 2010;363(8):711-723.
Chapman PB, Hauschild A, Robert C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine. 2011;364(26):2507-2516.
Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. New England Journal of Medicine. 2014;371(20):1877-1888.
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2015;372(26):2521-2532.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2019;381(16):1535-1546.

Research Papers

Live PubMed searches for the latest peer-reviewed literature on skin cancer — each link runs a current query against the National Library of Medicine database:

Connections

Back to Table of Contents